These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12446446)

  • 21. Human T-cell leukemia virus type I or a related retrovirus in patients with mycosis fungoides/Sézary syndrome and Kaposi's sarcoma.
    Srivastava BI; Banki K; Perl A
    Cancer Res; 1992 Aug; 52(16):4391-5. PubMed ID: 1353704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument.
    McCaffrey S; Black RA; Nagao M; Sepassi M; Sharma G; Thornton S; Kim YH; Braverman J
    J Med Internet Res; 2019 Jan; 21(1):e11302. PubMed ID: 30617041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
    Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
    Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Seroepidemiology of Epstein-Barr virus and cytomegalovirus among Israeli male young adults.
    Levine H; Balicer RD; Rozhavski V; Halperin T; Shreberk M; Davidovitch N; Huerta-Hartal M; Ankol OE
    Ann Epidemiol; 2012 Nov; 22(11):783-8. PubMed ID: 22831994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients.
    Lebowitz E; Geller S; Flores E; Pulitzer M; Horwitz S; Moskowitz A; Kheterpal M; Myskowski PL
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):108-114. PubMed ID: 30176169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
    Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
    J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
    Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
    Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009.
    Talpur R; Singh L; Daulat S; Liu P; Seyfer S; Trynosky T; Wei W; Duvic M
    Clin Cancer Res; 2012 Sep; 18(18):5051-60. PubMed ID: 22850569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of treatments for mycosis fungoides and Sézary syndrome: nationwide survey responses.
    Gettler SL; Fung MA
    Dermatol Online J; 2005 Dec; 11(3):6. PubMed ID: 16409902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for cytomegalovirus reactivation after liver transplantation: can pre-transplant cytomegalovirus antibody titers predict outcome?
    Bruminhent J; Thongprayoon C; Dierkhising RA; Kremers WK; Theel ES; Razonable RR
    Liver Transpl; 2015 Apr; 21(4):539-46. PubMed ID: 25597303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of seropositivity of human T lymphotropic virus type 1 in mycosis fungoides patients and normal volunteers: a case-control study and review of literature.
    Seirafi H; Farnaghi F; Firooz A; Mostafa S; Talaei-Khoei M; Davari P; Gorouhi F
    Indian J Dermatol Venereol Leprol; 2009; 75(4):363-7. PubMed ID: 19584460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mycosis fungoides and Sezary syndrome are not associated with HTLV-I infection: an international study.
    Bazarbachi A; Soriano V; Pawson R; Vallejo A; Moudgil T; Matutes E; Peries J; Molina A; de The H; Schulz TF; Catovsky D; Gill PS
    Br J Haematol; 1997 Sep; 98(4):927-33. PubMed ID: 9326191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome.
    Suzuki SY; Ito K; Ito M; Kawai K
    J Dermatol Sci; 2010 Jan; 57(1):37-43. PubMed ID: 19931424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiology and prognostic factors for mycosis fungoides and Sézary syndrome in a multi-ethnic Asian cohort: a 12-year review.
    Lim HLJ; Tan EST; Tee SI; Ho ZY; Boey JJJ; Tan WP; Tang MBY; Shen L; Chan YH; Tan SH
    J Eur Acad Dermatol Venereol; 2019 Aug; 33(8):1513-1521. PubMed ID: 30801779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical severity measures and quality-of-life burden in patients with mycosis fungoides and Sézary syndrome: comparison of generic and dermatology-specific instruments.
    Herbosa CM; Semenov YR; Rosenberg AR; Mehta-Shah N; Musiek AC
    J Eur Acad Dermatol Venereol; 2020 May; 34(5):995-1003. PubMed ID: 31630443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of cytomegalovirus antibodies in blood donors at the National Blood Transfusion Centre, Nairobi.
    Njeru DG; Mwanda WO; Kitonyi GW; Njagi EC
    East Afr Med J; 2009 Dec; 86(12 Suppl):S58-61. PubMed ID: 21591511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
    Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
    Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and titre of antibodies to cytomegalovirus and epstein-barr virus in patients with autism spectrum disorder.
    Gentile I; Zappulo E; Bonavolta R; Maresca R; Messana T; Buonomo AR; Portella G; Sorrentino R; Settimi A; Pascotto A; Borgia G; Bravaccio C
    In Vivo; 2014; 28(4):621-6. PubMed ID: 24982232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factor analysis in mycosis fungoides/Sézary syndrome.
    Diamandidou E; Colome M; Fayad L; Duvic M; Kurzrock R
    J Am Acad Dermatol; 1999 Jun; 40(6 Pt 1):914-24. PubMed ID: 10365922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.